Please enter exact key words
Novel Bispecific Antibody Therapeutics

for the Treatment of Solid Tumors

Home / Available Projects / Novel Bispecific Antibody Therapeutics
Drug Name GPCR-targeted Project 007

A bispecific antibody that simultaneously targets two cancer stem cell receptors (LGR5 and LGR4) is in early preclinical development for the treatment of solid tumors.

Target Leucine-rich repeat-containing G protein-coupled receptor 4 (LGR4); Leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5)
Drug Modality Bispecific antibody
Indication Solid tumors
Product Category Biologic
Mechanism of Action G protein-coupled receptor antagonists
Status Preclinical
Patent Granted

More Detail Available Upon Request

We look forward to hearing from you.

Our customer service representatives are available 24 hours a day, from Monday to Sunday Online Inquiry

Protheragen's business is growing rapidly after founded in Ronkonkoma, New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.

Protheragen Inc.